Pittler MH, Ernst E (2003). Pittler, Max H, ed. "Kava extract for treating anxiety".Cochrane database of systematic reviews (Online) (1): CD003383.doi:10.1002/14651858.CD003383. ببمد: 12535473.
a b c d e Sarris J, LaPorte E, Schweitzer I (2011). "Kava: a comprehensive review of efficacy, safety, and psychopharmacology". Aust N Z J Psychiatry 45 (1): 27–35. doi:10.3109/00048674.2010.522554. ببمد: 21073405.
Olsen LR, Grillo MP, Skonberg C (2011). "Constituents in kava extracts potentially involved in hepatotoxicity: a review". Chem. Res. Toxicol. 24 (7): 992–1002. doi:10.1021/tx100412m. ببمد: 21506562.
6Singh YN, Singh NN (2002). "Therapeutic potential of kava in the treatment of anxiety disorders". CNS Drugs 16 (11): 731–43. doi:10.2165/00023210-200216110-00002. ببمد: 12383029.
Ligresti A, Villano R, Allarà M, Ujváry I, Di Marzo V (2012). "Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB₁ receptor ligand". Pharmacol. Res. 66 (2): 163–9. doi:10.1016/j.phrs.2012.04.003.ببمد: 22525682.
:a b Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner W (2001)."Interaction of various Piper methysticum cultivars with CNS receptors in vitro".Planta Med. 67 (4): 306–11. doi:10.1055/s-2001-14334. ببمد: 11458444.
Baum SS, Hill R, Rommelspacher H (1998). "Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats". Prog. Neuropsychopharmacol. Biol. Psychiatry 22 (7): 1105–20. doi:10.1016/s0278-5846(98)00062-1. ببمد: 9829291.
Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie J (2003). "Saccade and cognitive function in chronic kava users". Neuropsychopharmacology 28 (2): 389–96. doi:10.1038/sj.npp.1300052. ببمد: 12589393.
Sarris, J; Laporte, E; Schweitzer, I (2011). "Kava: A comprehensive review of efficacy, safety, and psychopharmacology". The Australian and New Zealand journal of psychiatry 45 (1): 27–35. doi:10.3109/00048674.2010.522554.ببمد: 21073405.
Lechtenberg, M.; Quandt, B.; Schmidt, M.; Nahrstedt, A. (2008). "Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products?". Die Pharmazie 63 (1): 71–74. ببمد: 18271308.
:a b Teschke, Rolf; Samuel Qiu; Vincent Lebot (September 2011). "Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits". Digestive and Liver Disease 43 (9): 676–681. doi:10.1016/j.dld.2011.01.018. ببمد: 21377431.
Clouatre, D. L. (2004). "Kava kava: Examining new reports of toxicity". Toxicology Letters 150 (1): 85–96. doi:10.1016/j.toxlet.2003.07.005. ببمد: 15068826.
Clough A (2001). "Enough! or too much. What is 'excessive' kava use in Arnhem Land?". Drug Alcohol Rev 22 (1): 43–51. doi:10.1080/0959523021000059820.ببمد: 12745358.
Mathews JD, Riley MD, Fejo L et al. (June 1988). "Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community".Med. J. Aust. 148 (11): 548–55. ببمد: 3374423.
Kava R (March 2001). "The adverse effects of kava". Pac Health Dialog 8 (1): 115–8. ببمد: 12017812.
Teschke, Rolf; Sarris, Jerome; Schweitzer, Isaac (2012). "Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited". British Journal of Clinical Pharmacology 73 (2): 170–4.doi:10.1111/j.1365-2125.2011.04070.x. PMC 3269575. ببمد: 21801196.
Teschke R, Sarris J, Glass X, Schulze J (March 2011). "Kava, the anxiolytic herb: back to basics to prevent liver injury?". Br J Clin Pharmacol 71 (3): 445–8.doi:10.1111/j.1365-2125.2010.03775.x. PMC 3045554. ببمد: 21284704.This raises the question as to whether noble cultivars may be better and safer regarding hepatotoxic effects than the medicinal kava varieties.
